Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.55 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.55 |
| ▸ | APP | P05067 | 4/20 | 0.49 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.43 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | NCF1 | P14598 | 2/20 | 0.42 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7797589 | 0.83 | APP (0.54) | KCNH2SCN5AAPPPDE10ANCF1 | |
| SCHEMBL21264107 | 0.83 | CHRNB2 (0.41) | KCNH2SCN5AAPPCHRNB2CHRNB4 | |
| SCHEMBL15539333 | 0.81 | APP (0.47) | KCNH2SCN5AAPPPDE10ANCF1 | |
| SCHEMBL20971411 | 0.81 | APP (0.47) | KCNH2SCN5AAPPPDE10AHSD11B1 | |
| SCHEMBL14252070 | 0.81 | CHRNB2 (0.42) | KCNH2SCN5AAPPCHRNB2CHRNB4 | |
| SCHEMBL12895814 | 0.81 | CACNA1C (0.56) | KCNH2SCN5AAPPCHRNB2CHRNB4 | |
| SCHEMBL5631959 | 0.81 | APP (0.47) | KCNH2SCN5AAPPPDE10ANCF1 | |
| SCHEMBL29907615 | 0.81 | APP (0.47) | KCNH2SCN5AAPPPDE10ANCF1 | |
| SCHEMBL12883344 | 0.79 | CHRNB2 (0.41) | KCNH2SCN5ACHRNB2CHRNB4CHRNA3 | |
| SCHEMBL11064636 | 0.79 | APP (0.46) | KCNH2SCN5AAPPPDE10ANCF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203007-A1 | PYRIDINYLACETAMIDE DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | X-CHEM GLOBAL HQ | 2023-06-29 | — | — | US | disclosed |
| US-10793564-B2 | Amino acid compounds and methods of use | PLIANT THERAPEUTICS, INC. (US) | 2020-10-06 | — | — | US | disclosed |
| US-20190276449-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2019-09-12 | — | — | US | disclosed |
| US-20190106427-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2019-04-11 | — | — | US | disclosed |
| US-20190100510-A1 | BROMOTRIAZOLE INTERMEDIATES | AMGEN INC. (US) | 2019-04-04 | — | — | US | disclosed |
| US-9573936-B2 | Triazole agonists of the APJ receptor | AMGEN INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-20160296592-A1 | Methods and Compositions for the Treatment of Proteinuric Diseases | THE GENERAL HOSPITAL CORPORATION | 2016-10-13 | — | — | US | disclosed |
| US-20100048536-A1 | Novel Substituted Diaryl Azepine Derivatives as Integrin Ligands | GENESTE HERVE | 2010-02-25 | — | — | US | disclosed |
| US-20070219233-A1 | Antitumor, antiinflammatory, antiarthritic agents, treating metastasis, restenosis, osteoporosis, macular degeneration, and diabetic retinopathy; 7-(2-{1-[1-(3-Benzyloxy-phenyl)-2-ethoxycarbonyl-vinyl]-1H-indol-5-yloxy}-ethyl)-3,4-dihydro-2H-[1,8]naphthyridine-1-carboxylic acid tert-butyl ester | LU TIANBO | 2007-09-20 | — | — | US | disclosed |
| US-7241789-B2 | Substituted indoles and their use as integrin antagonists | 3-DIMENSIONAL PHARMACEUTICAL, INC. (US) | 2007-07-10 | — | — | US | disclosed |
| EP-1390362-A1 | SUBSTITUTED BENZOFURANS AND BENZOTHIOPHENES, METHODS OF MAKING AND METHODS OF USE AS INTEGRIN ANTAGONISTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2004-02-25 | — | — | EP | disclosed |
| WO-2002088118-A1 | SUBSTITUTED BENZOFURANS AND BENZOTHIOPHENES, METHODS OF MAKING AND METHODS OF USE AS INTEGRIN ANTAGONISTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2002-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160296592-A1 | Methods and Compositions for the Treatment of Proteinuric Diseases | ITGB3, PLAUR, PROC | KCNH2 2085/4885SCN5A 717/4885APP 1116/4885 |
| US-20070219233-A1 | Antitumor, antiinflammatory, antiarthritic agents, treating metastasis, restenosis, osteoporosis, macular degeneration, and diabetic retinopathy; 7-(2-{1-[1-(3-Benzyloxy-phenyl)-2-ethoxycarbonyl-vinyl]-1H-indol-5-yloxy}-ethyl)-3,4-dihydro-2H-[1,8]naphthyridine-1-carboxylic acid tert-butyl ester | ITGA5, ADGRE5, ITGAV | KCNH2 706/4885SCN5A 912/4885APP 1632/4885 |
| US-20100048536-A1 | Novel Substituted Diaryl Azepine Derivatives as Integrin Ligands | ITGB3, ITGAL, ITGB4 | KCNH2 1086/4885SCN5A 338/4885APP 2989/4885 |
| US-20190100510-A1 | BROMOTRIAZOLE INTERMEDIATES | APH1A, BRDT, APH1B | KCNH2 4734/4885SCN5A 4739/4885APP 2789/4885 |
| US-10793564-B2 | Amino acid compounds and methods of use | ITGB6, ITGA6, ITGA5 | KCNH2 2136/4885SCN5A 85/4885APP 2093/4885 |
| US-20190276449-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA6, ITGA5 | KCNH2 2136/4885SCN5A 85/4885APP 2093/4885 |
| US-20230203007-A1 | PYRIDINYLACETAMIDE DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | SCN1A, SCN3A, SCN2A | KCNH2 52/4885SCN5A 14/4885APP 411/4885 |
| US-20190106427-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | WEE1, WEE2, NME1 | KCNH2 4651/4885SCN5A 4757/4885APP 4816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.